Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 59.6.
Basel Medical Group's Days Inventory for the
six
months ended in Dec. 2025 was 37.07.
Basel Medical Group's Days Payable for the
six
months ended in Dec. 2025 was 159.06.
Therefore, Basel Medical Group's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was -62.39.
Basel Medical Group (NAS:BMGL) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Basel Medical Group Cash Conversion Cycle Related Terms
Basel Medical Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Basel Medical Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMGL vs AMS, HLYK, BICX: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Basel Medical Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's Cash Conversion Cycle falls into.
Basel Medical Group Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Basel Medical Group's Cash Conversion Cycle for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basel Medical Group (BMGL) has a Cash Conversion Cycle of -62.39 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Basel Medical Group and its competitors.
Is Basel Medical Group's Cash Conversion Cycle too high?
Basel Medical Group's current Cash Conversion Cycle is -62.39. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's Cash Conversion Cycle compare to AMS and HLYK?
Basel Medical Group's Cash Conversion Cycle of -62.39 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.91, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Basel Medical Group and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current Cash Conversion Cycle is -62.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current Cash Conversion Cycle of -62.39. The current Cash Conversion Cycle is -62.39. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current Cash Conversion Cycle is -62.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
